Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Regeneron books full U.S. Eylea sales, and 80% of its Eylea-related revenue comes from the U.S. Blockbuster immunology drug Dupixent so far generates 80% of its sales in the U.S., and Regeneron is ...

RELATED: Regeneron's Sanofi deal finally turns a profit, thanks to Dupixent Even Regeneron’s established blockbusters are facing some significant challenges, SVB Leerink said.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Regeneron Pharmaceuticals, Inc. REGN announced that the blockbuster asthma drug Dupixent (dupilumab) has been recommended by the European Medicines Agency’s Committee for Medicinal Products for ...

Regeneron REGN 2.04% Pharmaceuticals and Sanofi SAN 2.54% have won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive ...